SG52475A1 - Cytosine deaminsae negative selection system for gene transrer techniques and therapies - Google Patents
Cytosine deaminsae negative selection system for gene transrer techniques and therapiesInfo
- Publication number
- SG52475A1 SG52475A1 SG1996005053A SG1996005053A SG52475A1 SG 52475 A1 SG52475 A1 SG 52475A1 SG 1996005053 A SG1996005053 A SG 1996005053A SG 1996005053 A SG1996005053 A SG 1996005053A SG 52475 A1 SG52475 A1 SG 52475A1
- Authority
- SG
- Singapore
- Prior art keywords
- gene
- therapies
- cytosine
- deaminsae
- transrer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Exchange Systems With Centralized Control (AREA)
- Brushes (AREA)
- Devices For Checking Fares Or Tickets At Control Points (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/725,076 US5358866A (en) | 1991-07-03 | 1991-07-03 | Cytosine deaminase negative selection system for gene transfer techniques and therapies |
Publications (1)
Publication Number | Publication Date |
---|---|
SG52475A1 true SG52475A1 (en) | 1998-09-28 |
Family
ID=24913069
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG1996005053A SG52475A1 (en) | 1991-07-03 | 1992-06-30 | Cytosine deaminsae negative selection system for gene transrer techniques and therapies |
Country Status (12)
Country | Link |
---|---|
US (2) | US5358866A (fr) |
EP (1) | EP0595873B1 (fr) |
JP (1) | JP3386461B2 (fr) |
AT (1) | ATE191505T1 (fr) |
AU (1) | AU667820B2 (fr) |
CA (1) | CA2112395C (fr) |
DE (1) | DE69230882T2 (fr) |
DK (1) | DK0595873T3 (fr) |
ES (1) | ES2152929T3 (fr) |
GR (1) | GR3033909T3 (fr) |
SG (1) | SG52475A1 (fr) |
WO (1) | WO1993001281A1 (fr) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6337209B1 (en) | 1992-02-26 | 2002-01-08 | Glaxo Wellcome Inc. | Molecular constructs containing a carcinoembryonic antigen regulatory sequence |
CA2042093C (fr) * | 1990-05-09 | 2002-12-24 | Gyula Hadlaczky | Lignee de cellules renfermant un exces de centromeres mammaliens |
US6555370B1 (en) * | 1990-11-13 | 2003-04-29 | Immunex Corporation | Bifunctional selectable fusion genes |
US5358866A (en) * | 1991-07-03 | 1994-10-25 | The United States Of America As Represented By The Department Of Health And Human Services | Cytosine deaminase negative selection system for gene transfer techniques and therapies |
WO1993010218A1 (fr) * | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vecteurs comprenant des genes etrangers et des marqueurs selectifs negatifs |
FR2683725B1 (fr) * | 1991-11-15 | 1995-07-07 | Pasteur Institut | Composition cellulaire pour le traitement des organismes humains ou animaux. |
AU675948B2 (en) * | 1992-05-01 | 1997-02-27 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The | Bystander effect tumoricidal therapy |
AU6953394A (en) * | 1993-05-21 | 1994-12-20 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
JPH10503641A (ja) * | 1994-05-02 | 1998-04-07 | ユニバーシティ オブ ワシントン | チミジンキナーゼ変異体 |
US6451571B1 (en) | 1994-05-02 | 2002-09-17 | University Of Washington | Thymidine kinase mutants |
WO1995030763A2 (fr) | 1994-05-09 | 1995-11-16 | Chiron Viagene, Inc. | Vecteurs retroviraux a taux de recombinaison reduit |
US6013517A (en) | 1994-05-09 | 2000-01-11 | Chiron Corporation | Crossless retroviral vectors |
US5856153A (en) * | 1994-11-17 | 1999-01-05 | Cayla | Suicide genes and new associations of pyrimidine nucleobase and nucleoside analogs with new suicide genes for gene therapy of acquired diseases |
US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
US6638762B1 (en) * | 1994-11-28 | 2003-10-28 | Genetic Therapy, Inc. | Tissue-vectors specific replication and gene expression |
US20020068049A1 (en) * | 1998-09-10 | 2002-06-06 | Henderson Daniel R. | Tissue specific adenoviral vectors |
WO1997015668A2 (fr) * | 1995-10-23 | 1997-05-01 | Board Of Regents, The University Of Texas System | Procedes et compositions comprenant glut-2 et des chimeres de glut-2 |
DE19704979A1 (de) * | 1996-02-07 | 1997-08-14 | Max Delbrueck Centrum | Retroviraler Vektor für den Gentransfer eines IL6-Antagonisten in humane hämatopoetische Stammzellen |
US6077697A (en) * | 1996-04-10 | 2000-06-20 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
US6025155A (en) * | 1996-04-10 | 2000-02-15 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
US20030033617A1 (en) | 1996-04-10 | 2003-02-13 | Gyula Hadlaczky | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
US20020160970A1 (en) * | 1996-04-10 | 2002-10-31 | Gyula Hadlaczky | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
US6566089B1 (en) * | 1996-09-04 | 2003-05-20 | Tularik Inc. | Cell-based drug screens for regulators of gene expression |
EP1054979A4 (fr) | 1998-02-19 | 2002-03-27 | St Jude Childrens Res Hospital | Compositions et procedes servant a sensibiliser et a inhiber la croissance de cellules cancereuses humaines |
GB9810752D0 (en) * | 1998-05-19 | 1998-07-15 | Glaxo Group Ltd | Cystosine deaminase gene |
US20020115213A1 (en) * | 1998-08-14 | 2002-08-22 | Northeastern Ohio Universities Of Medicine | Engraftable neural progenitor & stem cells for brain tumor therapy |
US7186409B2 (en) | 1998-08-14 | 2007-03-06 | The Children's Medical Center Corporation | Neural stem cells and use thereof for brain tumor therapy |
US5958767A (en) | 1998-08-14 | 1999-09-28 | The Children's Medical Center Corp. | Engraftable human neural stem cells |
FR2794025A1 (fr) * | 1999-05-25 | 2000-12-01 | Transgene Sa | Composition destinee a la mise en oeuvre d'un traitement antitumoral ou antiviral chez un mammifere |
US6656917B1 (en) * | 1999-06-30 | 2003-12-02 | Marker Gene Technologies, Inc. | Compositions and methods for targeted enzymatic release of cell regulatory compounds |
US8716558B2 (en) | 1999-06-30 | 2014-05-06 | Marker Gene Technologies, Inc. | Method of altering glycosylation of proteins in response to nojirimycin glucuronide in a plant cell expressing glucuronidase |
WO2001068148A1 (fr) * | 2000-03-15 | 2001-09-20 | Children's Medical Center Corporation | Vecteurs de transfert de genes systemiques utilises pour le traitement des tumeurs |
US6579522B1 (en) * | 2000-06-27 | 2003-06-17 | Genvec, Inc. | Replication deficient adenoviral TNF vector |
PT1322752E (pt) * | 2000-09-28 | 2010-05-06 | Bioriginal Food & Science Corp | Fad4, fad5, fad5-2 e fad6, novos membros da família de dessaturases de ácidos gordos e susas utilizações |
EP1264891A1 (fr) * | 2001-05-31 | 2002-12-11 | Plant Research International B.V. | Modification du génome vegetal par recombinaison dirigée inductible des transgenes |
WO2003012030A2 (fr) * | 2001-08-01 | 2003-02-13 | University Of Utah, Technology Transfer Office | Inhibiteurs et activateurs selectifs d'isoformes de phosphodiesterases nucleotidiques cycliques pde3 |
US20030086903A1 (en) * | 2001-11-02 | 2003-05-08 | Genvec, Inc. | Therapeutic regimen for treating cancer |
CA2493364A1 (fr) * | 2002-07-26 | 2004-02-12 | Basf Plant Science Gmbh | Nouveaux procedes de selection |
US20040149174A1 (en) * | 2003-02-05 | 2004-08-05 | Mbt Holding Ag | Accelerating admixture for concrete |
AU2004263274B2 (en) | 2003-07-21 | 2009-11-05 | Transgene S.A. | Novel multifunctional cytokines |
CA2532783C (fr) | 2003-07-21 | 2013-09-17 | Transgene S.A. | Polypeptide a activite cytosine-desaminase amelioree |
ATE458500T1 (de) * | 2003-11-14 | 2010-03-15 | Genvec Inc | Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc). |
CA2558273A1 (fr) * | 2004-03-17 | 2005-09-29 | Basf Plant Science Gmbh | Controle post-recolte de culture genetiquement modifiee utilisant des composes d'acides amines d |
WO2005090581A1 (fr) * | 2004-03-17 | 2005-09-29 | Basf Plant Science Gmbh | Constructions ameliorees pour l'excision de marqueur basee sur un marqueur de selection a double fonction |
ATE491799T1 (de) | 2004-05-26 | 2011-01-15 | Bayer Schering Pharma Ag | Chimäre adenoviren zur verwendung in der krebsbehandlung |
EP1781784A2 (fr) | 2004-08-02 | 2007-05-09 | BASF Plant Science GmbH | Procede pour l'isolement de sequences de terminaison de transcription |
EP1874938B1 (fr) | 2005-04-19 | 2012-04-04 | BASF Plant Science GmbH | Expression spécifique de l'albumen farineux et/ou de l'embryon en germination dans des plantes monocotylédonées |
US20070026012A1 (en) | 2005-08-01 | 2007-02-01 | Cornell Research Foundation, Inc. | Compositions and methods for monitoring and altering protein folding and solubility |
WO2007024877A2 (fr) | 2005-08-22 | 2007-03-01 | Cornell Research Foundation, Inc. | Compositions et methodes permettant d'analyser des interactions de proteines |
CA2675926A1 (fr) | 2007-02-16 | 2008-08-21 | Basf Plant Science Gmbh | Sequences d'acides nucleiques pour la regulation de l'expression specifique de l'embryon dans des plantes monocotyles |
US20090196854A1 (en) * | 2008-02-04 | 2009-08-06 | Kytos Biosystems S.A. | Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based delivery |
WO2010045002A2 (fr) | 2008-09-26 | 2010-04-22 | Tocagen Inc. | Vecteurs de thérapie génique et cytosines déaminases |
EP2248903A1 (fr) | 2009-04-29 | 2010-11-10 | Universitat Autònoma De Barcelona | Procédés et réactifs pour le transfert génétique efficace et ciblé vers des monocytes et macrophages |
US9605844B2 (en) * | 2009-09-01 | 2017-03-28 | Cree, Inc. | Lighting device with heat dissipation elements |
BR122021015693B1 (pt) | 2011-12-21 | 2022-05-03 | Cj Cheiljedang Corporation | Microrganismo produtor de lisina e método para a produção de l-lisina |
EP3473708B1 (fr) | 2012-07-24 | 2021-01-27 | The General Hospital Corporation | Traitement par virus oncolytique de tumeurs résistantes |
AU2014338864C1 (en) | 2013-10-25 | 2020-07-16 | Akamis Bio Limited | Oncolytic adenoviruses armed with heterologous genes |
US20160303174A1 (en) | 2013-12-11 | 2016-10-20 | The General Hospital Corporation | Stem cell delivered oncolytic herpes simplex virus and methods for treating brain tumors |
EP3129037B1 (fr) | 2014-04-10 | 2019-11-13 | Transgene | Vecteurs oncolytiques poxviraux |
EP3283529B1 (fr) | 2015-04-17 | 2023-06-07 | The General Hospital Corporation | Agents, systèmes et méthodes de traitement du cancer |
IL284375B (en) | 2015-04-30 | 2022-07-01 | Psioxus Therapeutics Ltd | A replication-competent group b oncolytic adenovirus |
BR112018012180A2 (pt) | 2015-12-17 | 2018-12-04 | Psioxus Therapeutics Ltd | vírus de codificação de um anticorpo ou fragmento de complexo anti-tcr |
GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
KR102371151B1 (ko) | 2020-03-13 | 2022-03-07 | 주식회사 큐로셀 | 항-bcma 결합 영역, 이를 포함하는 융합단백질, 및 이를 포함하는 조성물 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4975278A (en) * | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
CA2018273C (fr) * | 1989-06-09 | 1999-04-06 | Peter D. Senter | Cytosine deaminase thermostable |
GB8919607D0 (en) * | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
US5358866A (en) * | 1991-07-03 | 1994-10-25 | The United States Of America As Represented By The Department Of Health And Human Services | Cytosine deaminase negative selection system for gene transfer techniques and therapies |
-
1991
- 1991-07-03 US US07/725,076 patent/US5358866A/en not_active Expired - Lifetime
-
1992
- 1992-06-30 JP JP50225093A patent/JP3386461B2/ja not_active Expired - Fee Related
- 1992-06-30 DE DE69230882T patent/DE69230882T2/de not_active Expired - Fee Related
- 1992-06-30 AU AU22959/92A patent/AU667820B2/en not_active Ceased
- 1992-06-30 ES ES92915347T patent/ES2152929T3/es not_active Expired - Lifetime
- 1992-06-30 SG SG1996005053A patent/SG52475A1/en unknown
- 1992-06-30 EP EP92915347A patent/EP0595873B1/fr not_active Expired - Lifetime
- 1992-06-30 CA CA002112395A patent/CA2112395C/fr not_active Expired - Fee Related
- 1992-06-30 WO PCT/US1992/005385 patent/WO1993001281A1/fr active IP Right Grant
- 1992-06-30 AT AT92915347T patent/ATE191505T1/de not_active IP Right Cessation
- 1992-06-30 DK DK92915347T patent/DK0595873T3/da active
-
1994
- 1994-07-07 US US08/271,874 patent/US5624830A/en not_active Expired - Lifetime
-
2000
- 2000-07-05 GR GR20000401594T patent/GR3033909T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
AU667820B2 (en) | 1996-04-18 |
DE69230882D1 (de) | 2000-05-11 |
EP0595873A4 (fr) | 1994-12-07 |
US5358866A (en) | 1994-10-25 |
US5624830A (en) | 1997-04-29 |
ES2152929T3 (es) | 2001-02-16 |
CA2112395A1 (fr) | 1993-01-21 |
JP3386461B2 (ja) | 2003-03-17 |
WO1993001281A1 (fr) | 1993-01-21 |
DE69230882T2 (de) | 2000-11-09 |
CA2112395C (fr) | 2008-04-22 |
AU2295992A (en) | 1993-02-11 |
GR3033909T3 (en) | 2000-11-30 |
ATE191505T1 (de) | 2000-04-15 |
EP0595873A1 (fr) | 1994-05-11 |
DK0595873T3 (da) | 2000-07-10 |
EP0595873B1 (fr) | 2000-04-05 |
JPH07501925A (ja) | 1995-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG52475A1 (en) | Cytosine deaminsae negative selection system for gene transrer techniques and therapies | |
EP0500917A4 (en) | Recombinant herpes simplex viruses vaccines and methods | |
DK0506945T3 (da) | Fremgangsmåde til genoverførsel under anvendelse af retrotransposoner | |
ES8705036A1 (es) | Procedimiento para preparar una vacuna que comprende un polipeptido fijado a una membrana | |
EP0088195A3 (fr) | RNA-messager, production et utilisation de celui-ci | |
CA2182303A1 (fr) | Procede de preparation d'un vecteur viral par recombinaison homologue intermoleculaire | |
AU7335296A (en) | Recombinant sendai virus | |
ATE270342T1 (de) | Endosomolytisch wirksame partikel | |
HK1018287A1 (en) | (-)-strand rna virus vector having autonomously replicating activity | |
AU8067698A (en) | Chimeric vectors comprising a phage packaging site and a portion derived from a genome of a eukaryotic virus | |
NZ315357A (en) | Method for industrially producing a japanese encephalitis vaccine, and resulting vaccine | |
Litzkas et al. | Efficient transfer of cloned DNA into human diploid cells: protoplast fusion in suspension | |
AU4307197A (en) | Herpesvirus saimiri as viral vector | |
NZ304076A (en) | cell culture methods to produce neural cells population with an introduced positive selective marker | |
IL148360A0 (en) | A herpes viral mutant and pharmaceutical compositions containing the same | |
Doersen et al. | Cytoplasmic inheritance of erythromycin resistance in human cells. | |
EP0326127A3 (fr) | Mutants d'insertion du virus de la rhinotrachéite infectieuse bovine, vaccins qui les contiennent et procédé pour leur préparation et applications | |
MX9707910A (es) | Vector viral recombinante inducible por la glucosa. | |
IL118942A0 (en) | Avirulent herpetic viruses useful as tumericidal agents and vaccines | |
ES2003462A6 (es) | Un metodo de obtencion de un alto nivel de expresion de una proteina. | |
AU2190288A (en) | Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained | |
Mullen et al. | Cytosine deaminase negative selection system for gene transfer techniques and therapies | |
AU5153196A (en) | Diagnostic and therapeutic system for Crohn's Disease and colitia ulcerosa | |
ES2000404A6 (es) | Un metodo de transformacion del actinomiceto streptomyces wadayamensis | |
Coleman | Comparison of the abilities of free and membrane-bound polyribosomes isolated from exponential-phase cells of Bacillus amyloliquefaciens to incorporate amino acids into protein. |